Users Coming Off Weight-Loss Injections Put On Pounds Far More Rapidly Than Dieters

Fresh analysis suggests that individuals who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who end traditional lifestyle programs.

Published data in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.

"Users using these medications need to be informed of the risk of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.

Such speed of regain implies a reversion to original mass in about 18 months.

Comparing Therapies

The research, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.

Scientists point out that people who lose weight through dieting generally experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.

The Reason for the Rapid Rebound

Doctors propose the mode of action of the injections accounts for the accelerated rebound.

The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Artificially providing the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable."

An Ongoing Issue?

Medical guidelines advise the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

Many experts contend that, given the likelihood of weight regain, the treatment might need to be ongoing.

This view is reinforced by pharmaceutical companies, who state that the results "highlight the chronic character of obesity," similar to managing conditions like high blood pressure.

Patient Testimonies

Individuals who have discontinued the jabs describe a intense return of appetite.

"It was like a trigger that goes on and you become starving," described a patient.

This difficulty is worsened if users have not established sustainable dietary or behavioural modifications during therapy.

Widespread Adoption

Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.

• Adoption is higher among women compared to males.
• The 40s and 50s demographic shows the greatest usage rates.
• A large proportion access the drugs through private prescriptions rather than the NHS.

Finally, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and lasting health benefits hinges on combined lifestyle changes.